BioLargo

US: BLGO

$25.5m market cap

$0.18 last close

BioLargo has a number of subsidiaries and products focused on using iodine chemistry. CupriDyne is a product that is currently on the market for industrial odor control. The subsidiary Clyra Medical is a wound care company with an iodine-based irrigation solution and SkinDisc, a cell therapy for wounds. It is developing the AOS as a low-cost water purification device. Finally, the company has a full service environmental engineering team.

Investment summary

BioLargo reported record revenue in 2018 of $1.4m, more than doubling from the previous year, with the majority of this revenue attributable to Odor-No-More at $1.1m. Odor-No-More continues to improve its margins and is expected to break even by the end of 2019. Moreover, it expects to provide the data needed to complete a 510(k) for its Clyra wound care product in six months, with a spin-off planned for around the end of 2019, and for the Advanced Oxidation System (AOS) to be commercially available in late 2019 or early 2020 and eventually operating independently.

Sector
Healthcare
Share price graph
Price performance
%
1m
3m
12m
Actual (1.7) (20.7) (34.6)
Relative* 0.6 (22.3) (37.5)
52-week high/low US$0.4/US$0.2
*% relative to local index
Key management
Dennis Calvert President & CEO